Celldex Therapeutics Inc (CLDX) 27.87 $CLDX
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 7.37 (-0.09), KITE: 57.68 (-2.30), CLDX: 27.87 (+0.03), JUNO: 60.66 (-0.09)
Celldex: An Immuno-Oncology Play With Monster Potential
DoconStocks - at Seeking Alpha - Mon Mar 30, 5:17PM CDT
CLDX: 27.87 (+0.03), BMY: 64.50 (-1.26)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 37.96 (-0.54), CLDX: 27.87 (+0.03), LGND: 77.11 (+0.88)
Celldex Therapeutics Has Returned 17.6% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Tue Mar 24, 11:34AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 4 weeks, Celldex Therapeutics has returned 17.64% as of today's recent price of $28.84.
CLDX: 27.87 (+0.03)
Celldex Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 6.09%
Comtex SmarTrend(R) - Mon Mar 23, 5:40PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $28.29 to a high of $30.50. Yesterday, the shares fell 6.1%, which took the trading range below the 3-day low of $29.70 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 27.87 (+0.03)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.52 (-0.12), MDT: 77.99 (-0.43), CLDX: 27.87 (+0.03), FOMX: 9.25 (-0.05), AMGN: 159.85 (-4.45), AET: 106.53 (-2.04), NKTR: 11.00 (-0.31), CELG: 115.28 (-4.74), HUM: 178.02 (-3.16), CANF: 2.23 (+0.03), ANTM: 154.41 (-2.44), NVO: 53.39 (-1.29), GILD: 98.13 (-2.56), GERN: 3.77 (-0.10), AZN: 68.43 (-1.51), CLLS: 34.58 (-0.62), WCG: 91.46 (-0.87), FOLD: 10.88 (-0.09), REGN: 451.48 (-8.30), CUR: 1.90 (-0.05)
After Yesterday's Rally of 3.89% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 19, 4:39PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $30.61 to a high of $32.82. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $32.08 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 27.87 (+0.03)
Celldex, Roche Ink Deal to Develop Kidney Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 2:22PM CDT
Celldex (CLDX) entered into an agreement with Roche to evaluate varlilumab with the latter's MPDL3280A for renal cell carcinoma.
LCI: 67.71 (-0.15), CLDX: 27.87 (+0.03), BMY: 64.50 (-1.26)
Celldex teams up with Roche in cancer immunotherapy trial
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 11:13AM CDT
CLDX: 27.87 (+0.03)
27.3% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Mar 17, 9:46AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 3 weeks, Celldex Therapeutics has returned 27.27% as of today's recent price of $31.20.
CLDX: 27.87 (+0.03)
Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A
GlobeNewswire - Tue Mar 17, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.
CLDX: 27.87 (+0.03)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 297.62 (-7.14), PCYC: 255.95 (-0.48), ITEK: 5.42 (+0.23), REDX: (), PTX: 10.69 (+0.17), CLDX: 27.87 (+0.03), ILMN: 185.64 (-1.98), IDGX: (), ACAD: 32.59 (-0.76), TRGT: 2.97 (-0.03), CLLS: 34.58 (-0.62), EXAC: 25.63 (+0.21), ABBV: 58.54 (+0.30), CRMD: 9.84 (+1.14), AGMX: (), ZGNX: 1.37 (unch), VVUS: 2.46 (-0.06), SPPI: 6.07 (-0.04), GSK: 46.15 (-1.05), OREX: 7.83 (+0.08), SQNM: 3.95 (+0.04), IRWD: 16.00 (-0.53), GILD: 98.13 (-2.56), MRK: 57.48 (-0.86), OHRP: 2.54 (-0.27), TEVA: 62.30 (-0.22)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.95 (-0.48), CLDX: 27.87 (+0.03), EPZM: 18.78 (-0.80), STML: 14.47 (-0.61), JNJ: 100.60 (-0.95), ABBV: 58.54 (+0.30), INFI: 13.98 (-0.34), PTLA: 37.96 (-0.54), INCY: 91.66 (-2.53), PFE: 34.79 (-0.21), IMGN: 8.95 (+0.43), AMGN: 159.85 (-4.45), LLY: 72.65 (-1.22), BMY: 64.50 (-1.26), GSK: 46.15 (-1.05), SGEN: 35.35 (-0.75), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), TEVA: 62.30 (-0.22), CELGZ: 2.97 (+0.16), KPTI: 30.61 (-0.30), NVS: 98.61 (-2.70)
Celldex Rintega: Interim Data And Timeline For Approval
Kanak Kanti De - at Seeking Alpha - Fri Mar 13, 8:06AM CDT
CLDX: 27.87 (+0.03)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 46.33 (-0.75), NWBO: 7.37 (-0.09), ZIOP: 10.77 (-0.84), PCYC: 255.95 (-0.48), CVM: 1.05 (+0.01), PFE: 34.79 (-0.21), CLDX: 27.87 (+0.03), IMGN: 8.95 (+0.43), BMY: 64.50 (-1.26), RIGL: 3.57 (+0.22), INO: 8.16 (-0.17), KITE: 57.68 (-2.30), LH: 126.09 (-1.19), ABBV: 58.54 (+0.30), PBYI: 236.11 (-3.65)
12.7% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Mar 10, 9:21AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 2 weeks, Celldex Therapeutics has returned 12.75% as of today's recent price of $27.64.
CLDX: 27.87 (+0.03)
Where Celldex Is Concerned, Patience Will Be Required
Scrying Biotech - at Seeking Alpha - Mon Mar 09, 11:17AM CDT
CLDX: 27.87 (+0.03)
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 98.13 (-2.56), CLDX: 27.87 (+0.03), LLY: 72.65 (-1.22), BMY: 64.50 (-1.26)
Why Celldex Therapeutics, Inc. Is Soaring
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 04, 11:59AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in the clinical stage biotech ...
CLDX: 27.87 (+0.03)
Celldex's underwriters exercise option to purchase a further 1.088m common shares
M2 - Mon Mar 02, 5:04AM CST
Biopharmaceutical company Celldex Therapeutics (NasdaqGS:CLDX) revealed on Friday that the underwriters of its public offering have exercised in full their option to purchase an additional 1,087,500 shares of common stock at the public offering price of USD24.00.
CLDX: 27.87 (+0.03)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 7.37 (-0.09), KITE: 57.68 (-2.30), CLDX: 27.87 (+0.03), JUNO: 60.66 (-0.09)
Celldex: An Immuno-Oncology Play With Monster Potential
DoconStocks - at Seeking Alpha - Mon Mar 30, 5:17PM CDT
CLDX: 27.87 (+0.03), BMY: 64.50 (-1.26)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 37.96 (-0.54), CLDX: 27.87 (+0.03), LGND: 77.11 (+0.88)
Celldex Therapeutics Has Returned 17.6% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Tue Mar 24, 11:34AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 4 weeks, Celldex Therapeutics has returned 17.64% as of today's recent price of $28.84.
CLDX: 27.87 (+0.03)
Celldex Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 6.09%
Comtex SmarTrend(R) - Mon Mar 23, 5:40PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $28.29 to a high of $30.50. Yesterday, the shares fell 6.1%, which took the trading range below the 3-day low of $29.70 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 27.87 (+0.03)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.52 (-0.12), MDT: 77.99 (-0.43), CLDX: 27.87 (+0.03), FOMX: 9.25 (-0.05), AMGN: 159.85 (-4.45), AET: 106.53 (-2.04), NKTR: 11.00 (-0.31), CELG: 115.28 (-4.74), HUM: 178.02 (-3.16), CANF: 2.23 (+0.03), ANTM: 154.41 (-2.44), NVO: 53.39 (-1.29), GILD: 98.13 (-2.56), GERN: 3.77 (-0.10), AZN: 68.43 (-1.51), CLLS: 34.58 (-0.62), WCG: 91.46 (-0.87), FOLD: 10.88 (-0.09), REGN: 451.48 (-8.30), CUR: 1.90 (-0.05)
After Yesterday's Rally of 3.89% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Mar 19, 4:39PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $30.61 to a high of $32.82. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $32.08 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 27.87 (+0.03)
Celldex, Roche Ink Deal to Develop Kidney Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 2:22PM CDT
Celldex (CLDX) entered into an agreement with Roche to evaluate varlilumab with the latter's MPDL3280A for renal cell carcinoma.
LCI: 67.71 (-0.15), CLDX: 27.87 (+0.03), BMY: 64.50 (-1.26)
Celldex teams up with Roche in cancer immunotherapy trial
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 11:13AM CDT
CLDX: 27.87 (+0.03)
27.3% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Mar 17, 9:46AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 3 weeks, Celldex Therapeutics has returned 27.27% as of today's recent price of $31.20.
CLDX: 27.87 (+0.03)
Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A
GlobeNewswire - Tue Mar 17, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.
CLDX: 27.87 (+0.03)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 297.62 (-7.14), PCYC: 255.95 (-0.48), ITEK: 5.42 (+0.23), REDX: (), PTX: 10.69 (+0.17), CLDX: 27.87 (+0.03), ILMN: 185.64 (-1.98), IDGX: (), ACAD: 32.59 (-0.76), TRGT: 2.97 (-0.03), CLLS: 34.58 (-0.62), EXAC: 25.63 (+0.21), ABBV: 58.54 (+0.30), CRMD: 9.84 (+1.14), AGMX: (), ZGNX: 1.37 (unch), VVUS: 2.46 (-0.06), SPPI: 6.07 (-0.04), GSK: 46.15 (-1.05), OREX: 7.83 (+0.08), SQNM: 3.95 (+0.04), IRWD: 16.00 (-0.53), GILD: 98.13 (-2.56), MRK: 57.48 (-0.86), OHRP: 2.54 (-0.27), TEVA: 62.30 (-0.22)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.95 (-0.48), CLDX: 27.87 (+0.03), EPZM: 18.78 (-0.80), STML: 14.47 (-0.61), JNJ: 100.60 (-0.95), ABBV: 58.54 (+0.30), INFI: 13.98 (-0.34), PTLA: 37.96 (-0.54), INCY: 91.66 (-2.53), PFE: 34.79 (-0.21), IMGN: 8.95 (+0.43), AMGN: 159.85 (-4.45), LLY: 72.65 (-1.22), BMY: 64.50 (-1.26), GSK: 46.15 (-1.05), SGEN: 35.35 (-0.75), GILD: 98.13 (-2.56), KITE: 57.68 (-2.30), MRK: 57.48 (-0.86), TEVA: 62.30 (-0.22), CELGZ: 2.97 (+0.16), KPTI: 30.61 (-0.30), NVS: 98.61 (-2.70)
Celldex Rintega: Interim Data And Timeline For Approval
Kanak Kanti De - at Seeking Alpha - Fri Mar 13, 8:06AM CDT
CLDX: 27.87 (+0.03)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 46.33 (-0.75), NWBO: 7.37 (-0.09), ZIOP: 10.77 (-0.84), PCYC: 255.95 (-0.48), CVM: 1.05 (+0.01), PFE: 34.79 (-0.21), CLDX: 27.87 (+0.03), IMGN: 8.95 (+0.43), BMY: 64.50 (-1.26), RIGL: 3.57 (+0.22), INO: 8.16 (-0.17), KITE: 57.68 (-2.30), LH: 126.09 (-1.19), ABBV: 58.54 (+0.30), PBYI: 236.11 (-3.65)
12.7% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Mar 10, 9:21AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 2 weeks, Celldex Therapeutics has returned 12.75% as of today's recent price of $27.64.
CLDX: 27.87 (+0.03)
Where Celldex Is Concerned, Patience Will Be Required
Scrying Biotech - at Seeking Alpha - Mon Mar 09, 11:17AM CDT
CLDX: 27.87 (+0.03)
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 3:45PM CST
Bristol-Myers Squibb announced encouraging data from a phase III study evaluating a once-daily combination of Daklinza and Gilead Sciences Inc.'s Sovaldi.
GILD: 98.13 (-2.56), CLDX: 27.87 (+0.03), LLY: 72.65 (-1.22), BMY: 64.50 (-1.26)
Why Celldex Therapeutics, Inc. Is Soaring
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 04, 11:59AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in the clinical stage biotech ...
CLDX: 27.87 (+0.03)
Celldex's underwriters exercise option to purchase a further 1.088m common shares
M2 - Mon Mar 02, 5:04AM CST
Biopharmaceutical company Celldex Therapeutics (NasdaqGS:CLDX) revealed on Friday that the underwriters of its public offering have exercised in full their option to purchase an additional 1,087,500 shares of common stock at the public offering price of USD24.00.
CLDX: 27.87 (+0.03)
